The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatment ...
Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration...
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study...
Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing,...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares...
U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares...
Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing...
On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000...